Sector Watch: Healthcare - Sep 06 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $118.42 -2.14 -1.78% | XBI: $96.69 -2.55 -2.57% | Updated Sep 06, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| ARWR52WH Arrowhead Pharmaceuticals $1.7B |
19.39+5.29 28.6 M 17.3x |
38% | ||
| CVM52WH Cel-Sci $78.6M |
3.34+0.39 7.0 M 6.4x |
13% | ||
| EVFM Evofem BioSciences $113.8M |
4.41+0.41 158.3 K |
10% | ||
| CCM Concord Medical Services Holdings $138.2M |
3.18+0.29 5.6 K 2.1x |
10% | ||
| EYPT Eyepoint Pharmaceuticals $125.4M |
2.32+0.20 1.1 M 5.0x |
9% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| DRNA Dicerna Pharmaceuticals $689.4M |
13.02-2.88 1.8 M 4.7x |
-18% | ||
| BLCM Bellicum Pharmaceuticals $270.9M |
6.25-0.73 558.6 K |
-10% | ||
| SGMO Sangamo BioSciences $1.3B |
13.05-1.50 7.3 M 2.7x |
-10% | ||
| GALT Galectin Therapeutics $222.6M |
5.44-0.61 1.0 M |
-10% | ||
| NTLA Intellia Therapeutics $1.2B |
27.07-2.99 471.7 K |
-10% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit | Business Wire [businesswire.com]Dicerna Announces Proposed Follow-On Public Offering of Common Stock | Business Wire [businesswire.com]
Alacrita Appoints Peter Traber to Lead Consulting on Antifibrotic Drug Development [prnewswire.com]
EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU? [globenewswire.com]
NIH Selects CEL-SCI?s LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program | Business Wire [businesswire.com]
Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria | Business Wire [businesswire.com]
EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information [globenewswire.com]
Tmunity Names Graeme Bell as Chief Financial Officer and Executive Vice President | Business Wire [businesswire.com]
Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease | Business Wire [businesswire.com]
Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences | Business Wire [businesswire.com]
Dicerna to Participate in Upcoming Investor Conferences | Business Wire [businesswire.com]
Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott ? Fundamental Analysis, Key Performance Indications [globenewswire.com]
Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September [globenewswire.com]
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors | Business Wire [businesswire.com]
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia | Business & Finance | manchestertimes.com [prnewswire.com]
Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference [globenewswire.com]
New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix ? Consolidated Revenues, Company Growth, and Expectations for 2018 [globenewswire.com]
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences [globenewswire.com]
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors | Business & Finance | manchestertimes.com [businesswire.com]
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia [prnewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
